Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
2 Biotech Stocks That Could Soar This Year
11:45am, Monday, 12'th Jan 2026
Both biotechs are a bit risky, but could benefit from clinical progress this year -- and the upside would be huge. CRISPR has three promising candidates in early development as well as its only approv
CRISPR Therapeutics (CRSP) Is Considered a Good Investment by Brokers: Is That True?
10:30am, Monday, 12'th Jan 2026
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones
08:36am, Monday, 12'th Jan 2026
-2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY ® launch acceleration continues, supporting multi-billion-dollar potential- -Broad pipeline supported by leading g
First Look: Risk-Off on Powell Probe, Deals and Policy Moves
07:38am, Monday, 12'th Jan 2026
Stock News Risk-off after DOJ probe of Fed chair: Bank shares including JPMorgan (JPM), Bank of America (BAC), Citigroup (C) and Capital One (COF) fell as futur
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
06:50pm, Friday, 09'th Jan 2026
CRISPR Therapeutics AG (CRSP) closed at $53.84 in the latest trading session, marking a -4.54% move from the prior day.
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of “Hold” from Analysts
02:00am, Wednesday, 07'th Jan 2026
Shares of CRISPR Therapeutics AG (NASDAQ: CRSP - Get Free Report) have earned an average recommendation of "Hold" from the twenty-two analysts that are currently covering the stock, Marketbeat.com rep
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why
07:00pm, Monday, 05'th Jan 2026
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $55.16, representing a +2.58% change from its previous close.
CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
08:30am, Monday, 05'th Jan 2026
ZUG, Switzerland and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dis
Crispr Therapeutics: Prospects For 2026 - Why I Believe Casgevy Is Key
12:31pm, Friday, 02'nd Jan 2026
Crispr Therapeutics AG commands a $5bn valuation, anchored by Casgevy's commercial approval and robust clinical data in SCD and TDT. Casgevy's slow commercial ramp is expected to accelerate in 2026, w
Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks
05:06pm, Wednesday, 31'st Dec 2025
The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 will be the definitive coming-out party for the genomic revolution.
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know
06:50pm, Tuesday, 30'th Dec 2025
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.19, moving 1.45% from the previous trading session.
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock
10:01am, Tuesday, 30'th Dec 2025
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
TSLA: Cathie Wood Dumps $30 Million Worth Tesla Stock
12:51pm, Monday, 29'th Dec 2025
Cathie Wood's Ark Invest increased stakes in gene-editing and autonomous mobility companies while trimming holdings in Tesla (TSLA) and Rocket Lab (RKLB).Sellin
These 2 Healthcare Stocks Beat the Market in 2025. Should You Buy Them in 2026?
06:00am, Friday, 26'th Dec 2025
CRISPR Therapeutics could perform well again next year, provided its clinical success continues. HCA Healthcare's prospects for next year remain uncertain, but its long-term outlook is strong.
Is CRISPR Therapeutics Stock Yesterday's News?
04:15am, Wednesday, 24'th Dec 2025
CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company's stock, once a highflier, has declined from its peak.
